Tissue Repair Ltd (TRP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tissue Repair Ltd (TRP) has a cash flow conversion efficiency ratio of -0.339x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-4.01 Million ≈ $-2.84 Million USD) by net assets (AU$11.83 Million ≈ $8.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Tissue Repair Ltd to measure how much of total assets are equity-financed.
Tissue Repair Ltd - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Tissue Repair Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Tissue Repair Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
Tissue Repair Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tissue Repair Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
South HARZ Potash Ltd
AU:SHP
|
-0.877x |
|
Triple Point Social Housing REIT PLC
LSE:SOHO
|
0.034x |
|
GLOW LIFETECH CORP.
F:9DO
|
0.054x |
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
-0.039x |
|
Rincon Resources Ltd
AU:RCR
|
-0.029x |
|
NedSense Enterprises NV
AS:NEDSE
|
0.068x |
|
Future Fintech Group Inc
NASDAQ:FTFT
|
-0.035x |
|
NCL International Logistics Public Company Limited
BK:NCL
|
-0.560x |
Annual Cash Flow Conversion Efficiency for Tissue Repair Ltd (2020–2025)
The table below shows the annual cash flow conversion efficiency of Tissue Repair Ltd from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Tissue Repair Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$13.91 Million ≈ $9.84 Million |
AU$-3.70 Million ≈ $-2.62 Million |
-0.266x | +3.12% |
| 2024-06-30 | AU$18.04 Million ≈ $12.76 Million |
AU$-4.95 Million ≈ $-3.50 Million |
-0.274x | -41.14% |
| 2023-06-30 | AU$21.88 Million ≈ $15.48 Million |
AU$-4.26 Million ≈ $-3.01 Million |
-0.194x | -24.24% |
| 2022-06-30 | AU$25.34 Million ≈ $17.93 Million |
AU$-3.97 Million ≈ $-2.81 Million |
-0.157x | -396.87% |
| 2021-06-30 | AU$27.07 Million ≈ $19.16 Million |
AU$-852.89K ≈ $-603.47K |
-0.032x | +95.15% |
| 2020-06-30 | AU$999.90K ≈ $707.50K |
AU$-649.98K ≈ $-459.91K |
-0.650x | -- |
About Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It develops TR-987, a topical … Read more